Pursuant to Regulation 30(6) read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bliss GVS Pharma has informed that the Company has completed the commissioning & qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. It is equipped with state of the art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention. The unit is spread on an overall area of about 200,000 sq.ft. and is intended to further augment the production capacities for the Company. ‘The company has a robust pipeline of formulations ready at its R&D unit for WHO Pre qualification along with US and EU Markets for Tech-Transfer & Scale Up for this unit and foresee a healthy business growth from its new Unit. In line with commitment towards sustainability, a significant portion of the energy requirement of this facility will be met by captive solar power generation units’ said Gagan Harsh Sharma, Vl-Strategy & Business Development, of the company. The Company has received necessary permissions for the facility from the relevant authorities to commence tech-transfer/ validation activities.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |